Repligen to buy BioLife in $1.5 billion deal to expand cell therapy business
CTV News
—
Repligen Corp said on Wednesday it would buy BioLife Solutions in a cash-and-stock deal valued at about US$1.5 billion, to expand the drugmaking equipment provider’s presence in the fast-growing cell therapy market.